Agenda 2012: Through a glass, darkly
The political, regulatory, and marketing stories of the pharmaceutical industry in 2012 remain to be told, but the upcoming elections, the growing strength of generics and biosimilars, the explosive demand of emerging markets, and the ubiquity of social media are all expected to play leading roles.
By Joshua Slatko

mHealth + HTML5 = pharma in 2012
The technology is already in place; now pharma marketers will focus on enhancing behavioral integration and improving a patient’s mHealth experiences in 2012.
By Cara Latham

Top 10 pipelines: Tide turns for innovation
A surge in new drug approvals and prospects for 2012 could ease R&D productivity woes somewhat.
By Michael D. Christel

Partnering with mom
Mothers are natural information-seekers, eager to find the best ways to help their children grow into healthy adults. Frequently, they turn to nurses and other pediatric staff for nutrition tips and other educational resources, providing marketers the opportunity to relay customized materials to help them through the process.
By Cara Latham

To the point
By Christiane Truelove

Sales & Marketing
An underused strategy to reduce costs, increase efficiencies.
By Illysa Levins

Interactive & Digital Marketing
Barriers remain to e-prescribing.
By Joshua Slatko

Business
Pharma continues expansion in Asia.
By Cara Latham

The Leader's Edge
The best thing that could ever happen … to you: how career reversals can reinvigorate your life.
By Sander Flaum

People on the move
Pfizer Inc. has elected its current president and CEO, Ian Read, as chairman of the company’s board.
By Colette Pilkus

Ad Agency Update
Study: Pharma lacks multicultural digital approach.
By Cara Latham

FDA Focus
HHS overrules FDA on Plan B
By Cara Latham

Drug Approvals
Vyndaqel approved to delay peripheral neurologic impairment
By Colette Pilkus


Shot to the heart
The effect of generic competition to Lipitor will be felt by all statin brands, but companies can take steps to somewhat blunt the impact.
By Christiane Truelove 

Agenda, continued
Dozens of industry leaders discuss the Agenda 2012 topics and others in full interview transcripts.
By Joshua Slatko